Literature DB >> 23550155

c-Myc phosphorylation by PKCζ represses prostate tumorigenesis.

Ji Young Kim1, Tania Valencia, Shadi Abu-Baker, Juan Linares, Sang Jun Lee, Tomoko Yajima, Jing Chen, Alexey Eroshkin, Elias A Castilla, Laurence M Brill, Mario Medvedovic, Michael Leitges, Jorge Moscat, Maria T Diaz-Meco.   

Abstract

Studies showing reduced PKCζ expression or enzymatic activity in different types of human cancers support the clinical relevance of PKCζ as a tumor suppressor. However, the in vivo role of PKCζ and its mechanisms of action in prostate cancer remain unclear. Here we demonstrate that the genetic inactivation of PKCζ in mice results in invasive prostate carcinoma in vivo in the context of phosphatase and tensin homolog deficiency. Bioinformatic analysis of human prostate cancer gene-expression sets revealed increased c-Myc transcriptional activity in PKCζ-inactive cells, which correlated with increased cell growth, invasion, and metastasis. Interestingly, PKCζ knockdown or the overexpression of a kinase-inactive mutant resulted in enhanced cell proliferation and invasion in vitro through increased c-Myc mRNA and protein levels and decreased Ser-373 phosphorylation of c-Myc. Analysis of prostate cancer samples demonstrated increased expression and decreased phosphorylation of c-Myc at Ser-373 in PKCζ knockout tumors. In vivo xenograft studies revealed that c-Myc phosphorylation by PKCζ is a critical event in the control of metastasis. Collectively, these results establish PKCζ as an important tumor suppressor and regulator of c-Myc function in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23550155      PMCID: PMC3631641          DOI: 10.1073/pnas.1221799110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

Review 1.  MYC on the path to cancer.

Authors:  Chi V Dang
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

2.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.

Authors:  Daniel R Rhodes; Shanker Kalyana-Sundaram; Vasudeva Mahavisno; Radhika Varambally; Jianjun Yu; Benjamin B Briggs; Terrence R Barrette; Matthew J Anstet; Colleen Kincead-Beal; Prakash Kulkarni; Sooryanaryana Varambally; Debashis Ghosh; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

3.  MYC and Prostate Cancer.

Authors:  Cheryl M Koh; Charles J Bieberich; Chi V Dang; William G Nelson; Srinivasan Yegnasubramanian; Angelo M De Marzo
Journal:  Genes Cancer       Date:  2010-06

Review 4.  Of the atypical PKCs, Par-4 and p62: recent understandings of the biology and pathology of a PB1-dominated complex.

Authors:  J Moscat; M T Diaz-Meco; M W Wooten
Journal:  Cell Death Differ       Date:  2009-08-28       Impact factor: 15.828

5.  Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-kappaB activation and invasive prostate carcinoma.

Authors:  Pablo J Fernandez-Marcos; Shadi Abu-Baker; Jayashree Joshi; Anita Galvez; Elias A Castilla; Marta Cañamero; Manuel Collado; Carmen Saez; Gema Moreno-Bueno; Jose Palacios; Michael Leitges; Manuel Serrano; Jorge Moscat; Maria T Diaz-Meco
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-26       Impact factor: 11.205

6.  Overexpression of protein kinase C-zeta (PKC-zeta) inhibits invasive and metastatic abilities of Dunning R-3327 MAT-LyLu rat prostate cancer cells.

Authors:  C T Powell; J E Gschwend; W R Fair; N J Brittis; D Stec; R Huryk
Journal:  Cancer Res       Date:  1996-09-15       Impact factor: 12.701

7.  aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6.

Authors:  Hitoshi Ishiguro; Kazunori Akimoto; Yoji Nagashima; Yasuyuki Kojima; Takeshi Sasaki; Yukari Ishiguro-Imagawa; Noboru Nakaigawa; Shigeo Ohno; Yoshinobu Kubota; Hiroji Uemura
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-02       Impact factor: 11.205

8.  Integration of external signaling pathways with the core transcriptional network in embryonic stem cells.

Authors:  Xi Chen; Han Xu; Ping Yuan; Fang Fang; Mikael Huss; Vinsensius B Vega; Eleanor Wong; Yuriy L Orlov; Weiwei Zhang; Jianming Jiang; Yuin-Han Loh; Hock Chuan Yeo; Zhen Xuan Yeo; Vipin Narang; Kunde Ramamoorthy Govindarajan; Bernard Leong; Atif Shahab; Yijun Ruan; Guillaume Bourque; Wing-Kin Sung; Neil D Clarke; Chia-Lin Wei; Huck-Hui Ng
Journal:  Cell       Date:  2008-06-13       Impact factor: 41.582

9.  Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells.

Authors:  Barthelemy Diouf; Qing Cheng; Natalia F Krynetskaia; Wenjian Yang; Meyling Cheok; Deqing Pei; Yiping Fan; Cheng Cheng; Evgeny Y Krynetskiy; Hui Geng; Siying Chen; William E Thierfelder; Charles G Mullighan; James R Downing; Peggy Hsieh; Ching-Hon Pui; Mary V Relling; William E Evans
Journal:  Nat Med       Date:  2011-09-25       Impact factor: 53.440

10.  Down-regulation of PKCζ in renal cell carcinoma and its clinicopathological implications.

Authors:  Yeong-Shiau Pu; Chao-Yuan Huang; Jyue-Yu Chen; Wang-Yi Kang; Ying-Chu Lin; Yu-Shiang Shiu; Shu-Ju Chuang; Hong-Jeng Yu; Ming-Kuen Lai; Yu-Chieh Tsai; Wen-Jeng Wu; Tzyh-Chyuan Hour
Journal:  J Biomed Sci       Date:  2012-04-05       Impact factor: 8.410

View more
  27 in total

Review 1.  Protein kinase C as a tumor suppressor.

Authors:  Alexandra C Newton
Journal:  Semin Cancer Biol       Date:  2017-05-02       Impact factor: 15.707

Review 2.  The Dual Roles of the Atypical Protein Kinase Cs in Cancer.

Authors:  Miguel Reina-Campos; Maria T Diaz-Meco; Jorge Moscat
Journal:  Cancer Cell       Date:  2019-08-29       Impact factor: 31.743

Review 3.  Protein kinase C and cancer: what we know and what we do not.

Authors:  R Garg; L G Benedetti; M B Abera; H Wang; M Abba; M G Kazanietz
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

4.  HOIL-1L functions as the PKCζ ubiquitin ligase to promote lung tumor growth.

Authors:  Markus A Queisser; Laura A Dada; Nimrod Deiss-Yehiely; Martin Angulo; Guofei Zhou; Fotini M Kouri; Lawrence M Knab; Jing Liu; Alexander H Stegh; Malcolm M DeCamp; G R Scott Budinger; Navdeep S Chandel; Aaron Ciechanover; Kazuhiro Iwai; Jacob I Sznajder
Journal:  Am J Respir Crit Care Med       Date:  2014-09-15       Impact factor: 21.405

5.  Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer.

Authors:  Miguel Reina-Campos; Juan F Linares; Angeles Duran; Thekla Cordes; Antoine L'Hermitte; Mehmet G Badur; Munveer S Bhangoo; Phataraporn K Thorson; Alicia Richards; Tarmo Rooslid; Dolores C Garcia-Olmo; Syongh Y Nam-Cha; Antonio S Salinas-Sanchez; Ken Eng; Himisha Beltran; David A Scott; Christian M Metallo; Jorge Moscat; Maria T Diaz-Meco
Journal:  Cancer Cell       Date:  2019-02-28       Impact factor: 31.743

Review 6.  Protein kinase C in cancer: The top five unanswered questions.

Authors:  Mariana Cooke; Andrew Magimaidas; Victoria Casado-Medrano; Marcelo G Kazanietz
Journal:  Mol Carcinog       Date:  2017-03-10       Impact factor: 4.784

7.  Control of Paneth Cell Fate, Intestinal Inflammation, and Tumorigenesis by PKCλ/ι.

Authors:  Yuki Nakanishi; Miguel Reina-Campos; Naoko Nakanishi; Victoria Llado; Lisa Elmen; Scott Peterson; Alex Campos; Surya K De; Michael Leitges; Hiroki Ikeuchi; Maurizio Pellecchia; Richard S Blumberg; Maria T Diaz-Meco; Jorge Moscat
Journal:  Cell Rep       Date:  2016-09-20       Impact factor: 9.423

8.  Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis.

Authors:  Maria T Diaz-Meco; Jorge Moscat; Tania Valencia; Ji Young Kim; Shadi Abu-Baker; Jorge Moscat-Pardos; Christopher S Ahn; Miguel Reina-Campos; Angeles Duran; Elias A Castilla; Christian M Metallo
Journal:  Cancer Cell       Date:  2014-07-04       Impact factor: 31.743

9.  Protein Kinase C ζ Interacts with a Novel Binding Region of Gαq to Act as a Functional Effector.

Authors:  Guzmán Sánchez-Fernández; Sofía Cabezudo; Álvaro Caballero; Carlota García-Hoz; Gregory G Tall; Javier Klett; Stephen W Michnick; Federico Mayor; Catalina Ribas
Journal:  J Biol Chem       Date:  2016-02-17       Impact factor: 5.157

10.  IRF-1 mediates the suppressive effects of mTOR inhibition on arterial endothelium.

Authors:  Kai Peng; Xing Fan; Qiannan Li; Yiying Wang; Xiaolin Chen; Pingxi Xiao; Anthony G Passerini; Scott I Simon; ChongXiu Sun
Journal:  J Mol Cell Cardiol       Date:  2020-02-19       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.